Cingulate to Participate in the Healthcare Virtual Conference Part II Presented by Maxim Group and Hosted by M-Vest
June 14 2023 - 3:45PM
Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company
utilizing its proprietary Precision Timed Release™ (PTR™) drug
delivery platform technology to build and advance a pipeline of
next-generation pharmaceutical products, today announced that
Chairman and CEO Shane J. Schaffer, Pharm D, has been invited to
participate in the Healthcare Virtual Conference Part II, presented
by Maxim Group LLC and hosted by M-Vest. The three-day conference
will kick off
Tuesday, June 20th at 9:00 AM EST, and
conclude on Thursday, June 22nd.
Dr. Schaffer will partake in a company discussion on
Thursday, June 22nd at
10:30 AM EST.
The conference will be hosted live on M-Vest. To attend, sign up
to become an M-Vest member: Click Here to Reserve your
seat About the Healthcare Virtual Conference
Presented by Maxim and Hosted by M-VestThe exponential
growth in knowledge and expertise in science and medicine continues
to drive opportunities in the healthcare space. These include
multiple therapeutic categories and emerging technologies, which
our presenting companies at this year’s Maxim Healthcare Conference
are focused on, and for many, that includes key data-driven events
in 2023. Maxim Senior Analysts will host a wide range of
biotechnology and medical device companies in a series of
presentations and interactive discussions with CEOs and key
management. We will also be hosting several topical industry panels
that promise to be timely and engaging.
About Cingulate®Cingulate Inc. (NASDAQ: CING),
is a clinical-stage biopharmaceutical company utilizing its
proprietary PTR™ drug delivery platform technology to build and
advance a pipeline of next-generation pharmaceutical products,
designed to improve the lives of patients suffering from frequently
diagnosed conditions characterized by burdensome daily dosing
regimens and suboptimal treatment outcomes. With an initial focus
on the treatment of neurological disorders, Cingulate is
identifying and evaluating additional therapeutic areas where PTR™
technology may be employed to develop future product candidates,
including to treat anxiety disorders. Cingulate is headquartered in
Kansas City. For more information
visit Cingulate.com.
Investor Contact:Thomas DaltonVice President,
Investor & Public Relations,
Cingulate913-942-2301TDalton@cingulate.com
Matt KrepsDarrow Associates Investor
Relations214-597-8200mkreps@darrowir.com
Cingulate (NASDAQ:CING)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cingulate (NASDAQ:CING)
Historical Stock Chart
From Jul 2023 to Jul 2024